Development and Validation of a New Global AI Model Based on U.S. Clinical Data… Laying the Groundwork for U.S. Market Expansion

AITRICS (CEO Kwang Joon Kim), a company specializing in artificial intelligence(AI) technology announced on the 30 that it has signed a joint development agreement with Mayo Clinic Platform to develop and validate next-generation medical AI models.

Through this agreement, AITRICS has secured access to Mayo Clinic Platform’s extensive clinical datasets. Leveraging this data, the company aims to build models with broad applicability across diverse healthcare settings, while establishing a foundation for international performance and safety validation.

In addition, AITRICS has secured a strategic partnership that includes future rights and distribution collaboration, thereby establishing a long-term cooperative framework that spans from R&D to commercialization. The company plans to actively pursue business expansion in the U.S. and global markets.

Mayo Clinic Platform provides an infrastructure for the development and evaluation of medical AI based on Mayo Clinic’s world-class clinical data and research capabilities. This agreement is expected to serve as a turning point for AITRICS to strengthen its international credibility and accelerate its entry into the U.S. market.

Building on this collaboration, AITRICS will advance the development of new AI models optimized for the U.S. healthcare environment and initiate clinical trials in the U.S. for its patient deterioration prediction AI solution, AITRICS-VC (VitalCare).

Sia Park, Global Business Development Manager at AITRICS, stated “This agreement marks the first step in AITRICS’ full-scale entry into the U.S. and global healthcare markets, and a pivotal moment to broaden the horizons of future collaborations. By engaging in substantive cooperation with a world-class medical institution like Mayo Clinic, we will implement business strategies tailored to the U.S. environment and create sustainable growth on the global stage.”